Loading...
Loading...
Parent Project Muscular Dystrophy (PPMD) and Sarepta Therapeutics,
Inc.
today announced a new nationwide program from
PPMD to assist individuals with Duchenne muscular dystrophy in
accessing genetic testing. The program will be administered by PPMD,
a leading voice for patients and families impacted by Duchenne.
Support for the initiative will be provided by Sarepta, a developer
of innovative RNA-based therapeutics.
Through the new program, called Decode Duchenne, PPMD will offer
genetic testing at no cost to eligible patients who are unable to
access testing due to barriers such as a lack of or insufficient
insurance coverage. Decode Duchenne is expected to launch in the
fourth quarter of 2013 through PPMD's DuchenneConnect, an online
resource and registry for patients and families affected by Duchenne
and their healthcare providers. For patients with Duchenne, genetic
testing is used to identify the genetic mutation and confirm the
diagnosis. In addition, genetic testing can be used to determine a
patient's eligibility for certain clinical trials. Despite the
potential benefits of testing, in some cases patients are unable to
access genetic testing through their insurance provider.
"We believe all patients with Duchenne should have the opportunity to
receive genetic testing in order to understand their genetic
mutation, have confidence in their diagnosis and learn about
opportunities to participate in clinical trials of promising
investigational treatments," said Pat Furlong, president and chief
executive officer of PPMD. "This program seeks to address barriers to
genetic testing that have long frustrated the Duchenne community and
to help vulnerable patients and families."
"We are pleased to support Decode Duchenne, an important initiative
from PPMD and DuchenneConnect to help families and their physicians
navigate a sometimes difficult process to receive genetic testing,"
said Chris Garabedian, president and chief executive officer of
Sarepta Therapeutics. "Sarepta's support for this new program is part
of our broader commitment to develop new potential therapies, as well
as provide education and resources, that may help to improve outcomes
for boys and young men with Duchenne."
To participate in Decode Duchenne, patients must:
-- Have a confirmed diagnosis or be suspected of having Duchenne or
Becker muscular dystrophy based on clinical symptoms, as assessed by
their treating physician, and have a positive creatine kinase (CK)
test.
-- Have not previously had genetic testing, or must require additional
genetic testing to identify a causative mutation, as determined by the
DuchenneConnect Coordinator, a board-certified genetic counselor.
-- Provide documentation to confirm the patient's lack of insurance
coverage, insufficient insurance coverage, or a denial of coverage for
genetic testing.
-- Be citizens or legal residents of the United States.
-- Register on DuchenneConnect.
Additional eligibility criteria may apply, and the DuchenneConnect
Coordinator can help interested patients and their families determine
if they are eligible to participate.
Patients and families can learn more about the Decode Duchenne
genetic testing program by visiting DuchenneConnect at
www.duchenneconnect.org, or by contacting the DuchenneConnect
Coordinator at coordinator@duchenneconnect.org or (201) 937-1408.
Information is also available through Sarepta's new online resource
center Let's Skip Ahead, which is available at www.skipahead.com.
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in